Zimmer Biomet reports that most product lines impacted by previously disclosed shipping delays have returned to full shipping capacity, and disclosed the receipt of a Form 483 following an FDA inspection of a legacy Biomet manufacturing site in Warsaw, Indiana.
No patient safety concerns have been identified with products manufactured at the site.
Zimmer Biomet reports that most product lines impacted by previously disclosed shipping delays have returned to full shipping capacity, and disclosed the receipt of a Form 483 following an FDA inspection of a legacy Biomet manufacturing site in Warsaw,...
Zimmer Biomet reports that most product lines impacted by previously disclosed shipping delays have returned to full shipping capacity, and disclosed the receipt of a Form 483 following an FDA inspection of a legacy Biomet manufacturing site in Warsaw, Indiana.
No patient safety concerns have been identified with products manufactured at the site.
Copy to clipboard 
